5.80
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tetratherix
Its shares trade on ASX under the ticker TTX.AX. It has been listed since 30 June 2025. In the fiscal year to 30 June 2026, it reported revenue of A$918,151 and a net loss of A$9.3m. At that date it held total assets of A$53.2m and shareholders' equity of A$32.7m.
Tetratherix Ltd. engages in the development of a biostealth fluid matrix for regenerative medicine. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2025-06-30. The firm's biomaterial platform is built with polymer programming akin to Medical Lego to form implantable products to solve a range of clinical problems. The material is an injectable fluid to avoid causing damage to the body during its application. Upon injection, triggered by physiological temperature, a 3D matrix is formed that physically integrates and adheres to the target tissue. Tegenix and TegenEOS products are developed as a carrier designed to be mixed with a broad array of bone graft materials (BGMs) for dental, oral and orthopedic applications. TetraDerm products can be used in any surgical incision site to reduce scarring. Tutelix products are intended for use as a spacer to reduce side effects from radiation therapy in prostate cancer. The company has established its manufacturing center in Sydney, featuring a cleanroom production facility.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Jun 2025
- Website
- tetratherix.com ↗
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine with a polymer programming platform akin to Medical Lego.
- The company's injectable fluid forms a 3D matrix upon physiological temperature trigger, integrating with target tissue without causing damage.
- Tetratherix has established a manufacturing center in Sydney with a cleanroom production facility for its biomaterials.
Weaknesses
- The company's IPO is scheduled for 2025-06-30, indicating it is not yet publicly traded.
- Tetratherix has not yet commercialized its products, as all described applications are in development.
- The company's financial data is not provided, making it difficult to assess its current financial health.
Opportunities
- The company's biomaterial platform can be mixed with various bone graft materials for dental, oral, and orthopedic applications.
- TetraDerm products have potential for reducing scarring in surgical incision sites across multiple medical fields.
- Tutelix products offer a solution for reducing radiation therapy side effects in prostate cancer treatment.
Threats
- The company's reliance on a single biomaterial platform may limit its ability to address diverse medical needs.
- The biotechnology sector faces high regulatory hurdles for new medical products.
- The company's IPO date is in the future, which may delay access to capital for further development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.